SEC Comment Letter 0000000000-23-013039 to MANGOCEUTICALS, INC. (MGRX)

MANGOCEUTICALS, INC.
Date: Nov. 30, 2023 · CIK: 0001938046 · Accession: 0000000000-23-013039

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

Date

November 30, 2023

Author

Jacob D. Cohen

Form

UPLOAD

Company

MANGOCEUTICALS, INC.

Letter

United States securities and exchange commission logo November 30, 2023 Jacob D. Cohen Chief Executive Officer Mangoceuticals, Inc. 15110 N. Dallas Parkway, Suite 600 Dallas, TX 75248 Re:Mangoceuticals, Inc. Draft Registration Statement on Form S-1 Submitted November 24, 2023 CIK No. 0001938046 Dear Jacob D. Cohen: This is to advise you that we do not intend to review your registration statement. We request that you publicly file your registration statement no later than 48 hours prior to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Benjamin Richie at 202-551-7857 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: David M. Loev

Show Raw Text

United States securities and exchange commission logo
November 30, 2023
Jacob D. Cohen
Chief Executive Officer
Mangoceuticals, Inc.
15110 N. Dallas Parkway, Suite 600
Dallas, TX 75248
Re:Mangoceuticals, Inc.
Draft Registration Statement on Form S-1
Submitted November 24, 2023
CIK No. 0001938046
Dear Jacob D. Cohen:
            This is to advise you that we do not intend to review your registration statement.
            We request that you publicly file your registration statement no later than 48 hours prior
to the requested effective date and time. Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you that the company and its management are responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or
absence of action by the staff.
            Please contact Benjamin Richie at 202-551-7857 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:       David M. Loev

SecProbe.io